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CHAPTER I 
Introduction 
Anaesthesia for Functional endoscopic sinus surgery is a challenging job. The 
surgeons’ operating field itself is very small and surrounded with mucus 
membranes. It is imperative for the surgeons to look at a clear surgical field in 
order to identify the diseased tissue properly. A small amount of blood within the 
field is enough to occlude the view through the endoscope making things difficult 
for the surgeon and incomplete removal of the diseased tissue will cause the 
disease to reoccur. Anaesthesiologists have devised various techniques to prevent 
this bleeding, of which induced hypotension has stood the test of time. This 
surgery per se is not a major one by its standards and surgeons recently have been 
trying to accomplish FESS as a day care surgery. Different anaesthetic techniques 
using different pharmacological agents have been used to induce controlled 
hypotension. I have chosen to study and compare the effects of inhalational agent – 
sevoflurane based anaesthesia and intravenous agent – propofol based anaesthesia 
in reducing the intra operative blood loss.  
This study proposes to analyse the anaesthetic challenges of keeping the operating 
field free of blood through pharmacological therapy. It serves to study whether the 
traditional inhalational agent based anaesthesia – now sevoflurane anaesthesia in 
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our department scores over propofol based anaesthesia in providing better 
endoscopic vision for the surgeon.  
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CHAPTER II 
AIM 
To evaluate the effect of propofol versus sevoflurane anaesthesia as maintenance 
anaesthetics on the perioperative parameters of patients undergoing FESS under 
GA and controlled hypotension technique. 
The following parameters are compared: 
   1. Ability to achieve targeted MAP 
   2. Hemodynamic stability  
   3. Undesirable side effects 
   4. Blood loss 
5. Endoscopic vision 
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CHAPTER III 
Hypotensive anaesthesia 
Hypotensive anaesthesia is a technique, used intra operatively to help minimize 
surgical blood loss, thereby decreasing the need for blood transfusion and also to 
provide a clear surgical field. The technique entails the controlled lowering of 
blood pressure and is defined as a reduction of the systolic blood pressure to 
between 80-90 mmHg. An alternative definition is a decrease in the mean arterial 
pressure (MAP) to 50-70 mmHg in a normotensive patient.  
 
Inducing hypotension 
Deliberate hypotension is induced by a variety of pharmacological agents and non 
pharmacological methods. Since there is no single agent capable of safely and 
effectively lowering arterial pressure in all situations, the anaesthetist may need to 
employ a variety of agents or techniques in order to achieve the target pressure. 
 
Pharmacological agents can generally be divided into two categories: peripheral 
vasodilators and inhalation agents. 
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The three most commonly used vasodilators are: sodium nitroprusside (SNP), 
nitroglycerine (NTG) and trimethaphan.  
 
SNP acts as a vascular smooth muscle relaxant and has a rapid onset but brief 
duration of action. Its primary influence is on arteriolar and venous vessels, but 
without significant myocardial effects.  
 
NTG reduces blood pressure by relaxing venous smooth muscle and, like SNP, has 
rapid onset of action but short duration. NTG is less toxic than SNP. However, it is 
less potent than SNP in its capacity to reduce blood pressure.  
 
Trimethaphan produces hypotension through ganglionic blockade and direct 
vasodilator properties. It is also short acting and provides tight control of blood 
pressure. 
 
Commonly used inhalation agents, or volatile anaesthetic agents, include 
halothane, isoflurane and sevoflurane. The concentration of a volatile anaesthetic 
agent produces a dose dependent decrease in mean arterial pressure.  
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Alpha2 agonists and beta blockers are also used for this purpose. Spinal and 
epidural anaesthesia can also be used to produce controlled hypotension. 
Unfortunately, these techniques require large infusions of fluids and the deliberate 
hypotension can be erratic and difficult to control.  
 
Indications to hypotensive anaesthesia 
• Excision of intracranial tumors 
• Aneurysm excisions (Cerebral, carotid, aortic) 
• FESS procedure 
• Middle ear surgeries 
• Spine/hip surgeries 
 
Contraindications to hypotensive anaesthesia 
• Congenital heart disease 
• Severe anaemia 
• Coronary artery disease 
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• Congestive cardiac failure 
• Poorly controlled hypertension 
• Increased intracranial pressure 
• Significant cerebro-vascular disease 
• Low flow states to the liver or kidney 
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CHAPTER IV 
Functional Endoscopic Sinus Surgery 
Rhinology and sinus surgery have undergone a tremendous expansion since the 
discourses of Messerklinger and Wigand in the late 1970s. Imaging advances, 
increased understanding of the anatomy and the pathophysiology of chronic 
sinusitis, and image-guided surgery have allowed surgeons to perform more 
complex procedures with increased safety.  
                    
Functional endoscopic sinus surgery is the primary approach used today for the 
surgical treatment of chronic sinusitis. 
 
Indications 
Endoscopic sinus surgery is most commonly performed for inflammatory and 
infectious sinus disease. The most common indications for endoscopic sinus 
surgery are as follows: 
• Chronic sinusitis refractory to medical treatment 
• Recurrent sinusitis  
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• Nasal polyposis 
• Antrochoanal polyps 
• Sinus mucocoeles  
• Excision of selected tumours 
• Cerebrospinal fluid (CSF) leak closure 
• Orbital decompression (e.g., Grave’s ophthalmopathy) 
• Optic nerve decompression 
• Dacryocystorhinostomy (DCR) 
• Choanal atresia repair 
• Foreign body removal 
• Epistaxis control 
 
FESS is a delicate and time consuming procedure. It is performed routinely under 
general anaesthesia. Anaesthesiologists have to plan the technique in such a way 
that will facilitate the operating team for achieving a bloodless field for better 
visualization of the intranasal structures and minimize intra operative bleeding, 
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because even minimal bleeding can obstruct the view of the operating endoscope. 
Hence comes the role of hypotensive anaesthesia. Many pharmacological agents, 
including sevoflurane as a combination are in use for inducing intra operative 
hypotension. It is easy to administer and control its concentration, does not require 
infusion pump and can be quickly washed out from body by hyperventilation. As 
sevoflurane induces hypotension slower than the other pharmacological agents like 
sodium nitroprusside, continuous intra-arterial blood pressure monitoring is not 
mandatory. It causes least arrhythmia in presence of exogenous adrenaline which is 
routinely infiltrated into the operative field for creating a bloodless field. 
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CHAPTER V 
PHARMACOLOGY OF THE STUDY DRUGS 
SEVOFLURANE 
 
Sevoflurane is fluorinated methyl isopropyl ether used for inhalational anaesthesia.  
Physical properties 
Molecular weight              -        200 g/mol 
Boiling point at 1 atm       -         58.5º C 
Vapour pressure at 20ºC  -        170 mmHg 
Partition coefficient at 37ºC 
Blood – Gas                     -         0.69 
Brain – Blood                  -           1.7 
Fat – Blood                     -            48 
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Oil – Gas                        -             47.2 
MAC at PB 760 mmHg. 
30-55 years of age         -             1.8% 
For children 
0-1 month                       -              3.3% 
1-6 months                     -              3.0% 
6 months – 3 years         -              2.8% 
3-12 years                       -              2.5% 
 
Mechanism of action of inhaled anaesthetics 
Inhaled anaesthetics act in different ways at the level of the central nervous system. 
They may disrupt normal synaptic transmission by interfering with the release of 
neurotransmitters from presynaptic nerve terminal (enhance or depress inhibitory 
or excitatory transmission), by altering the re-uptake of neurotransmitters to the 
post synaptic receptor sites or by influencing the ionic conductance change that 
follows activation of the post synaptic receptor by neurotransmitters. Both pre and 
post synaptic effects have been found.  
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Direct interaction with the neuronal plasma membrane is very likely, but indirect 
action via production of a second messenger also remains possible. The high 
correlation between lipid solubility and anaesthetic potency suggests that 
inhalation anaesthetics have a hydrophobic site of action. Inhalation agents may 
bind to both membrane lipids and proteins. It is at this time not clear which of the 
different theories are most likely to be the main mechanism of action of inhalation 
anaesthetics. 
                     
The Meyer - Overton theory describes the correlation between lipid solubility of 
inhaled anaesthetics and MAC suggests that anaesthesia occurs when a significant 
number of inhalation anaesthetic molecules dissolve in the lipid cell membrane. 
The Meyer – Overton rule postulates that the number of molecules dissolved in the 
lipid cell membrane and not the type of inhalation agent causes anaesthesia. 
Combinations of different inhaled anaesthetics may have additive effects at the 
level of the cell membrane.  
                     
However, the Meyer – Overton theory does not describe why anaesthesia occurs. 
Mullins expanded the Meyer – Overton rule by adding the so-called Critical 
Volume Hypothesis. He states that the absorption of anaesthetic molecules could 
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expand the volume of a hydrophobic region within the cell membrane and 
subsequently distort channels necessary for sodium ion flux and the development 
of action potentials necessary for synaptic transmission. The fact that anaesthesia 
occurs with significant increase in volume of hydrophobic solvents and is 
reversible by compressing the volume of the expanded hydrophobic region of the 
cell membrane supports Mullins critical volume hypothesis. 
                     
The protein receptor hypothesis postulates that protein receptors in the central 
nervous system are responsible for the mechanism of action of inhaled 
anaesthetics. This theory is supported by the steep dose response curve for inhaled 
anaesthetics. However, it remains unclear if inhaled agents disrupt ion flow 
through membrane channels by an indirect action on the lipid membrane via a 
second messenger or by direct and specific binding to channel proteins.  
 
Another theory describes the activation of Gama Amino Butyric Acid (GABA) 
receptors by the inhalation anaesthetics. Volatile agents may activate GABA 
channels and hyperpolarize cell membranes. In addition, they may inhibit certain 
calcium channels and therefore prevent release of neurotransmitters and inhibit 
glutamate channels. Volatile anaesthetics share therefore common cellular actions 
with other sedative, hypnotic or analgesic drugs.  
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The true mechanism of action of volatile anaesthetics may be a combination of two 
or more such theories described as multisite action hypothesis. 
 
Pharmacokinetics 
Uptake and distribution of inhaled anaesthetics: 
A series of partial pressure gradients, beginning at the vaporizer of the anaesthetic 
machine, continuing in the anaesthetic breathing circuit, the alveolar tree, blood 
and tissue will ensure the forward movement of the gas. The principal objectives of 
that movement are to achieve equal partial pressure of the gas. After a short period 
of equilibration the alveolar partial pressure equals the brain partial pressure. 
Alveolar partial pressure can be raised by increasing minute ventilation, flow rates 
at the level of the vapourizer and by using a non-rebreathing circuit. 
Two special effects increasing the amount of gas in the alveoli have to be 
mentioned. The concentration effect describes how the concentration of the gas in 
the remaining alveolar volume can increase after some of the gas has been 
transferred into the blood. The second gas effect usually refers to nitrous oxide 
combined with an inhalation agent. Because nitrous oxide is not soluble in blood, 
its rapid absorption from alveoli causes an abrupt rise in the alveolar concentration 
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of the other inhalation anaesthetic. All the above mentioned factors influence the 
inflow of gas into the alveoli.  
  
Solubility, cardiac output and the alveolar to venous anaesthetic gradient represent 
outflow factors. Inflow factors minus outflow factors equals alveolar partial 
pressure of the gas. 
 
Solubility describes the affinity of the gas for a medium such as blood or fat tissue. 
 
The blood : gas partition coefficient describes how the gas will partition itself 
between the two phases after equilibrium has been reached. The blood : gas 
coefficient of sevoflurane (0.69) ensures prompt induction of anaesthesia after 
discontinuation of the anaesthetic. Compared with isoflurane, recovery from 
sevoflurane anaesthesia is faster and the difference is magnified in longer duration 
surgical procedures (>3 hours). 
 
A higher cardiac output removes more volatile anaesthetic from the alveoli and 
lowers therefore the alveolar partial pressure of the gas. The agent might be faster 
distributed within the body but the partial pressure in the arterial blood is lower. It 
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will take longer for the gas to reach equilibrium between the alveoli and the brain. 
Therefore, a high cardiac output prolongs induction time.  
 
The alveolar to venous partial pressure difference reflects tissue uptake of the 
inhaled anaesthetics. A large difference is caused by increased uptake of the gas 
during the induction phase. This facilitates the diffusion of the gas from the alveoli 
into the blood. The brain : blood coefficient describes how the gas will partition 
itself between the two phases after equilibrium has been reached. Sevoflurane for 
example has a brain : blood coefficient of 1.7 meaning that if the gas is in 
equilibrium, the concentration in the brain will be 0.7 times higher than the 
concentration in the blood. All inhalation anaesthetics have high fat : blood 
partition coefficients. This enormous capacity of fat for anaesthetic means that 
most of the anaesthetic contained in the blood perfusing fat is transferred to the fat. 
Although most of the anaesthetic moves from the blood into the fat, the anaesthetic 
partial pressure in fat increases very slowly. The large capacity of fat and its low 
perfusion per milliliter explains the delayed recovery in obese patients.  
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Pharmacodynamics 
Central nervous system 
Inhaled anaesthetics cause loss of response to verbal commands at MAC-awake 
concentrations. Surgical stimulation increases the anaesthetic requirement to 
prevent awareness.  
 
Volatile anaesthetics produce dose dependent increases in cerebral blood flow 
(CBF). Sevoflurane has an intrinsic dose dependent cerebral vasodilatory effect. 
Sevoflurane does not alter auto regulation of CBF. 
 
Inhaled anaesthetics produce increases in intracranial pressure that parallel 
increases in CBF produced by them. 
 
Inhaled anaesthetics produce dose dependent decreases in cerebral metabolic 
oxygen requirements (CMR O2). When EEG becomes isoelectric, an additional 
increase in the concentration of the volatile anaesthetics does not produce further 
decreases in CMR O2. 
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Cardiovascular system 
Volatile anaesthetics produce dose dependent decreases in mean arterial pressure. 
The decrease produced by sevoflurane principally results from a decrease in 
systemic vascular resistance. 
 
Sevoflurane increases heart rate only at concentrations of >1.5 MAC. A small dose 
of opioid (morphine in the preoperative medication or fentanyl intravenously 
immediately before induction of anaesthesia) can prevent the heart rate increase 
associated with volatile anaesthetics. 
 
Volatile anaesthetics exert little or no predictable effect on pulmonary vascular 
resistance. 
 
Sevoflurane has no effect on the atrioventricular or accessory  pathways and is 
considered an acceptable anaesthetic drug for patients undergoing ablative 
procedures. 
 
Volatile anaesthetics induce coronary vasodilatation by preferential action on 
vessels with diameters from 20µ to 50µ. They are cardio protective. 
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Respiratory system 
Volatile anaesthetics produce dose dependent increases in the frequency of 
breathing and decreases in tidal volume. The net effect is a rapid and shallow 
pattern of breathing. The increase in frequency of breathing is insufficient to offset 
decreases in tidal volume, leading to decreases in minute ventilation and increases 
in PaCO2. 
 
Sevoflurane decreases the ventilator response to carbon di oxide. It produces apnea 
between 1-5 and 2-0 MAC. All inhaled anaesthetics profoundly depress the 
ventilator response to hypoxemia. 
 
Sevoflurane produces bronchodilatation in normal individuals and in patients with 
COPD. 
 
Skeletal muscles 
Sevoflurane and other fluorinated ethers produce skeletal muscle relaxation and 
produce dose-dependent enhancement of the effects of neuromuscular blocking 
drugs.  
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Obstetrics 
Volatile anaesthetics produce dose dependent decreases in uterine smooth muscle 
contractility. This is desirable to facilitate removal of retained placenta. 
Conversely, uterine relaxation produced by volatile anaesthetics may contribute to 
blood loss due to uterine atony.  
 
Metabolism 
3 to 5% of the dose administered undergoes oxidative metabolism by cytochrome 
P-450 enzymes to form organic and inorganic fluoride metabolites. In addition, 
sevoflurane is degraded by dessicated carbon dioxide absorbents containing strong 
bases to potentially toxic compounds especially when the temperature is increased. 
Among these compounds, only compound A – Trifluromethyl vinyl ether (and to a 
lesser extent compound B) are encountered clinically. Compound A is a dose 
dependent nephrotoxin in animals. Although this finding is a concern, the levels of 
these compounds (particularly compound A) that occur during administration of 
sevoflurane to patients are far below speculated toxic levels. 
 
The rationale for utilizing at least 2litre/minute of fresh gas flow rate when 
administering sevoflurane is intended to minimize the concentration of compound 
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A that may accumulate in the anaesthesia breathing circuit to assess the adequacy 
of this recommendation, the concentration of compound A of anaesthesia with 1.25 
MAC sevoflurane during 2 to 8 hours was found to be in the range of 40 to 42 ppm 
which is far below the toxic levels. 
 
In children, sevoflurane anaesthesia lasting for 4 hours using total fresh gas flows 
of 2 litre/minute produced concentrations of compound A of <15 ppm and there 
was no evidence of renal dysfunction.  
 
A proposed mechanism of nephrotoxicity is metabolism of compound A via beta-
lyase pathway to a reactive thiol. Because humans have less than one-tenth of the 
enzymatic activity for this pathway compared to rats, it is possible that humans 
should be less vulnerable to injury by this mechanism. 
 
Probenecid is a selective inhibitor of organic anion transport and pretreatment with 
this drug prevents compound A induced renal injury in animals and may provide 
similar protection in humans.  
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Sevoflurane is non pungent, has minimal odour and causes the least degree of 
airway irritation among the currently available volatile anaesthetics. For these 
reasons, sevoflurane is acceptable for inhalation induction of anaesthesia. 
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PROPOFOL 
 
Propofol is a substituted isopropyl phenol (2,6 – di isopropyl phenol) that is 
administered intravenously as 1% solution in an aqueous solution of 10% soybean 
oil, 2.25% glycerol and 1.2% purified egg phosphatide. This drug is chemically 
distinct from all other drugs that act as intravenous sedative – hypnotics. 
 
Administration of propofol, 1.5 to 2.5 mg/kg as a rapid IV injection (<15 sec), 
produces unconsciousness within about 30 seconds. Awakening is more rapid and 
complete than that after induction of anaesthesia with all other drugs.   
 
The more rapid return of consciousness with minimal residual central nervous 
system effects is one of the most important advantages of propofol.  
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Mechanism of action 
Propofol is presumed to exert it’s sedative – hypnotic effects through an interaction 
with GABA receptor, the principal inhibitory neurotransmitter in the central 
nervous system. When GABA receptor is activated, transmembrane chloride 
conductance increases, resulting in hyprepolarisation of the post synaptic cell 
membrane and functional inhibition of the post synaptic neuron. The interaction of 
propofol with specific components of GABAA receptors appears to decrease the 
rate of dissociation of the inhibitory neurotransmitter, GABA from the receptor, 
thereby increasing the duration of the GABA activated opening of the chloride 
channel with resulting hyper polarization of cell membranes.  
 
Pharmacokinetics 
Propofol is rapidly metabolized in the liver by conjugation to glucuronide and 
sulphate to produce water-soluble compounds which are excreted by the kidneys. 
Less than 1% of Propofol is excreted unchanged in urine and 2% is excreted in 
faeces. As clearance of Propofol exceeds hepatic blood flow, extrahepatic 
metabolism and extrarenal elimination has been suggested. Lungs are responsible 
for approximately30% of the uptake and first-pass elimination after a bolus dose. 
During a continuous infusion of Propofol, there is a 20-30% decrease in Propofol 
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and a higher concentration of the metabolite 2,6-diisopropyl-1,4 quinol on the 
arterial side of the circulation. Despite the rapid clearance of Propofol by 
metabolism, there is no evidence of impaired elimination in patients with cirrhosis 
of the liver. Renal dysfunction does not influence the clearance of Propofol. The 
rapid clearance of Propofol confirms this drug can be administered as a continuous 
infusion without an excessive cumulative effect. 
 
By a three-compartment model, initial and slow distribution half-lines are 1 to 8 
minutes and 30 to 70 minutes and an elimination half-life of 4 – 23.5 hours. 
Volume of distribution of central compartment is 20-40 litres and volume of 
distribution at steady state (Vdss) is 150 – 700 litres (2-10 lit/kg). Clearance is 20-
30 ml/kg/min – 1.5 to 2.2 lit/min. It has a short effect site equilibration time 
equilibrium constant (Kev) for Propofol based on suppression of EEG is about 0.3 
min-1 
 
Pharmacodynamics 
Cardiovascular system 
Propofol produces decrease in arterial blood pressure during induction of 
anaesthesia. Induction dose of 2-2.5 mg/kg produces a 25-40% reduction in blood 
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pressure. Similar changes are seen in diastolic and mean blood pressure. The 
decrease in arterial pressure is associated with a decrease in cardiac output by 15% 
and decrease in systemic vascular resistance by 15-25%. The reduction in systemic 
pressure after an induction dose is due to vasodilatation and possibly myocardial 
depression. At high doses, 10 µg/ml, propofol abolishes the ionotropic effects of 
alpha but not beta stimulation and enhances lusitropic effect of beta stimulation. 
Vasodilatory effect is due to reduction in sympathetic activity.  
 
During maintenance of anaesthesia with propofol infusion, systolic pressure 
remains between 20 and 30% below preinduction levels. In patients receiving 
narcotic premedication and nitrous oxide with an infusion of propofol 54-104 
µg/kg/min, systemic vascular pressure is not significantly decreased from baseline 
but cardiac output and stroke volume are decreased. Because vasodilatory and 
myocardial depressant effects are concentration dependant, the decrease in blood 
pressure from propofol infusion is much less than that seen after an induction 
bolus. Heart rate may decrease, increase or remain unchanged when anaesthesia is 
maintained with propofol. Infusion of propofol results in significant reduction in 
both myocardial blood flow and myocardial oxygen consumption, a finding that 
suggests preservation of the global myocardial oxygen supply-demand ratio. 
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Respiratory system 
Propofol produces dose dependant depression of ventilation, with apnoea occurring 
in 25-35% of patients after induction of anaesthesia with propofol. Opioids given 
as premedication enhance ventilatory depressant effect. A maintenance infusion of 
propofol decreases tidal volume and respiratory rate.  
 
The ventilatory response to carbon di oxide and arterial hypoxemia are decreased 
by propofol. The decreased ventilatory response to hypercapnia is due to the effect 
at the central chemoreceptors. In contrast to low dose volatile anaesthetics, the 
peripheral chemoreflex response to carbon di oxide remains intact.  
 
Propofol can produce bronchodilatation and decrease the incidence of intra 
operative wheezing in patients with asthma. Propofol does not cause 
laryngospasm.  
 
Central nervous system 
Propofol is primarily a hypnotic. Induction dose is 1.5 to 2.5 mg/kg. Onset of 
hypnosis after doses of 2.5 mg/kg is rapid (one arm-brain circulation) 30-40 
seconds. Peak effect is seen at 90 to 100 seconds. Duration of hypnosis 5 to 10 
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min. Propofol decreases cerebral blood flow, cerebral metabolic oxygen 
consumption and intra cranial pressure. It also increases cerebrovascular resistance 
but does not appear to affect cerebrovascular reactivity to changes in arterial 
carbon di oxide tension.  
 
Other systems 
Propofol anaesthesia is associated with significant decreases in intraocular pressure 
by as much as 30-50%. This decrease may be associated with a concomitant 
decrease in systemic vascular resistance. 
 
Although propofol has the potential for affecting adrenal steroidogenesis, it does 
not appear to block cortisol and aldosterone secretion in response to surgical stress 
or adrenocorticotropic hormone in clinical practice. Although transient decreases 
in plasma cortisol concentration have occurred, these reductions have not been 
sustained.  
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Side effects 
Allergic reactions 
Allergic components of propofol include the phenyl nucleus and di isopropyl side 
chain. Allergic reactions are described in patients with history of other drug 
allergies often to neuromuscular blocking drugs.  
 
Lactic acidosis 
Also known as “propofol infusion syndrome” is described in patients receiving 
prolonged high dose infusions of propofol (>75 µ/kg/min) for longer than 24 
hours. Unexplained tachycardia during propofol anaesthesia should prompt 
evaluation. 
 
Other side effects include 
1. Abuse potential  
2. Bacterial growth – the contents of an opened vial must be discarded if they 
are not used within 6 hours. 
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3. Pain on injection – 1 ml 1% lignocaine injection prior to propofol 
administration decreases the incidence.  
 
Clinical uses 
Induction of anaesthesia 
The induction dose in healthy adults I s1.5 to 2.5 mg/kg IV, with blood levels of 2 
to 6 µg/ml producing unconsciousness depending on associated medications and 
the patient’s age. Awakening typically occurs at plasma propofol concentrations of 
1.0 to 1.5 µg/ml.  
 
Keo is the rate constant for equilibration between plasma and the site of drug effect 
(or) for transfer of drug from the site of drug effect to the environment. 
 
T1/2 keo for propofol is 2.4 minutes. 
 
By knowing the keo of propofol, we can design a dosing regimen that yields the 
desired concentration at the site of drug effect.  
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 Maintenance of anaesthesia 
Several infusion schemes have been used to achieve adequate plasma 
concentration of propofol after an induction dose, an infusion of 100-200 µ/kg/min 
is usually needed. The infusion rate is then titrated to individual requirements and 
the surgical stimulus. When combined with propofol, fentanyl reduces its required 
indusion rate and concentration.  
 
Drug 
conc. 
Skin 
incision 
Minor 
surgery 
Major 
surgery 
Awakening Analgesia 
or 
sedation 
µg/ml 2-6 2.5-7.5 2-6 0.8-1.8 1-3 
 
 
In our study, we have followed the Bristol regimen for maintenance of anaesthesia. 
We have used propofol infusion of 10 mg/kg/hour for the first 10 minutes followed 
by 8 mg/kg/hour for the next 10 minutes followed by 6 mg/kg/hour for rest of the 
procedure.  
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Antiemetic 
Sub hypnotic doses of propofol are effective against chemotherapy induced nausea 
and vomiting. When administered to induce and maintain anaesthesia, it is more 
effective than ondansetron in preventing PONV. Mechanism is unknown. 
 
Antipruritic 
Propofol, 10 mg IV, is effective in the treatment of pruritus associated with 
neuraxial opioids or cholestasis. The quality of analgesia is not affected by 
propofol.  
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CHAPTER VI 
REVIEW OF LITERATURE 
This study was constructed to evaluate whether propofol or sevoflurane as 
maintenance of anaesthesia offers any advantage for the conduct of hypotensive 
anaesthesia technique for patients undergoing FESS procedure under GA. The null 
hypothesis postulated for testing was that, there would be no difference between 
propofol and sevoflurane as maintenance anaesthesia in their effects on improved 
hemodynamic stability to reduce blood loss or improve endoscopic vision. 
Literature was reviewed to analyse the existence of similar studies. 
 
Sevaci et al1, in their study on ‘Comparison of propofol and sevoflurane  
anaesthesia by means of blood loss during endoscopic sinus surgery’, recruited 32 
ASA I or II adult patients. Induction was done in both groups with 2.5 mg/kg 
propofol, 0.5mg/kg rocuronium bromide and 2 µg/kg fentanyl.In Group 1 , 
Maintenance was 40/60% O2-air mixture with propofol infusion 12mg/kg/hr, 
9mg/kg/hr, 6mg/kg/hr for successive 30 minutes of surgery. They found that blood 
loss was significantly less in the propofol group. In Group 2 , maintenance was 
with 33/66% O2-N2O mixture and 2-2.5% sevoflurane.  
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Manola et al2, in their study on ‘Using remifentanil and sufentanil in functional 
endoscopic sinus surgery to improve surgical conditions’ recruited 71 patients . For 
maintenance of anesthesia, group A used sufentanil and sevoflurane, group B used 
remifentanil/propofol infusion and group C used fentanyl and isoflurane. They 
found that group B scored over group A and C in visibility of the surgical field and 
quantity of blood loss.  
 
Ahn et al3, in their study on ‘Comparison of surgical condition during propofol or 
sevoflurane anaesthesia for endoscopic sinus surgery’ recruited 40 ASA I/II 
patients. As maintenance, group 1 received propofol/remifentanil infusion and 
group 2 received sevoflurane/remifentanil infusion. They found that patients in 
propofol/remifentanil group had lesser blood loss and sevoflurane/remifentanil 
group. 
 
Wormald et al4, in their study on ‘The effect of total intravenous anaesthesia 
compared with inhalational anaesthesia on the surgical field during endoscopic 
sinus surgery’ recruited 56 ASA I, II patients. As maintenance of GA, group I 
received sevoflurane with fentanyl, group II received propofol and remifentanil 
infusion. They found that TIVA results in better surgical field than inhalational 
anaesthesia. 
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Tirelli et al5, in their study ‘Total intravenous anaesthesia in endoscopic sinus-
nasal surgery’ recruited 64 ASA I, II patients. Group I received TIVA using 
remifentanil and propofol. Group II used sevoflurane and fentanyl. They found that 
though the hypotensive effects of both groups is equivalent, only total intravenous 
anaesthesia is effective in reducing bleeding during functional endoscopic sinus-
nasal surgery. 
 
Blackwell et al6, in their study ‘Propofol for maintenance of general anaesthesia: a 
technique to limit blood loss during endoscopic sinus surgery’ retrospectively 
reviewed 25 patients. Group 1 had received propofol infusion for maintenance and 
group 2 received isoflurane as maintenance anaesthesia. They found that the 
average estimated blood loss was decreased in group 1.  
 
Eberhart et al7, in their study ‘Intravenous anaesthesia provides optimal surgical 
conditions during microscopic and endoscopic sinus surgery’ recruited 90 patients. 
Group 1 used propofol and remifentanil 10-30 µg/kg/hr. Group 2 received 
isoflurane 0.4-1% and repetitive doses of 0.5 to 1mg alfentanyl. An injectable 
vasodilator was used in both groups to keep mean arterial pressure between 60 and 
70mmHg. They found that intravenous anaesthesia using propofol – remifentanil 
provides better surgical condition compared with isoflurane – alfentanil. 
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Pavlin et al8, in their study ‘Propofol versus isoflurane for endoscopic sinus 
surgery’ recruited 56 patients.Group 1 received propofol, Group 2 received 
isoflurane, both groups supplemented with nitrous oxide\oxygen and alfentanil. 
They found that surgical blood loss was same for both anaesthetic agents , but 
propofol appeared to offer an advantage in terms of subjective improvement in 
operating conditions. 
 
Beule et al9, in their study ‘Propofol Vs Sevoflurane: bleeding in endoscopic sinus 
surgery’, recruited 46 patients. Group1 received maintenance with 
sevoflurane/fentanyl. Group 2 received maintenance with propofol/fentanyl. They 
found that under conditions of balanced circulatory parameters, equal blood loss 
and endoscopic vision can be achieved with both regimens. 
 
Cafiero et al10, in their study ‘Clinical comparison of remifentanil-sevoflurane Vs 
remifentanyl-propofol for endoscopic transsphenoidal surgery’, recruited 44 
patients. Group P received propofol and remifentanil. Group S received 
remifentanil and sevoflurane. They found that sevoflurane-remifentanil gives faster 
recovery and equivalent intra op status when compared with propofol group. 
 38
 
Shigeki et al11, in their study “comparative evaluation of total intravenous 
anaesthesia with propofol-fentanyl and thiopental –sevoflurane anaesthesia using 
laryngeal mask airway for diagnostic bronchoscopy” recruited 60 patients. Group 1 
was induced with propofol and fentanyl and maintained with continuous infusion 
of propofol with fentanyl. Group 2 was induced with thiopentone and maintained 
with N2O/O2/sevoflurane.Insertion of LMA was facilitated with vecuronium and 
ventilation was controlled. During maintenance of anaesthesia intra operative MAP 
was found to be lower and was maintained at that value.  
 
Steinmetz et al12, in their study “Hemodynamic differences between propofol-
remifentanil and sevoflurane anaesthesia for repair of cleft lip and palate in 
infants” recruited 39 infants. Group 1 received a combination of remifentanil and 
propofol. Group 2 received sevoflurane-fentanyl anaesthesia for surgical repair of 
cleft lip and palate. They found that remifentanil-propofol infusion was associated 
with lower heart rates than sevoflurane group. 
 
Zeliha et al13, in their study ‘Comparison of remifentanil-propofol and sevoflurane 
for preventing cardiovascular response and quality of recovery in pediatric 
surgery’ recruited 30 pediatric patients undergoing elective ENT surgery. They 
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found that TIVA provided lower preoperative heart rates and blood pressure than 
sevoflurane based anaesthesia. 
 
Jellish et al14, in their study ‘The comparative effect of sevoflurane versus 
propofol in the induction and maintenance of anaesthesia in adult patients’ 
recruited 186 ASA I, II patients undergoing elective surgical procedures of 1-3 
hours. Group I (n = 93) received sevoflurane-nitrous oxide for both induction and 
maintenance of anaesthesia while group 2 (n = 93) received propofol-nitrous oxide 
anaesthesia. They compared induction times, emergence time, complications, side 
effects and hemodynamic stability. They found that both groups were 
hemodynamically stable throughout the study period. 
 
Watson et al15, in their study “Clinical comparison of ‘single agent’ anaesthesia 
with sevoflurane versus target controlled infusion of propofol” recruited 40 
patients undergoing spinal surgery. Group 1 received propofol-air-oxygen for 
induction followed by propofol-air-oxygen for maintenance. Group 2 received 8% 
sevoflurane-oxygen for induction and sevoflurane-oxygen-nitrous oxide for 
maintenance. They found that cardiovascular stability was good and comparable in 
both groups.  
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CHAPTER VII 
MATERIALS AND METHODS 
After getting clearance from the ethics committee, the study was formulated as 
follows. 
 
Study design  
A prospective, randomized study 
 
Case definition 
Inclusion criteria 
• ASA I and II 
• Patients between ages 16 and 60 
• Patients undergoing endoscopic sinus surgery 
• Chronic sinusitis 
• Sinonasal polyposis 
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Exclusion criteria 
• Hypertensive patients 
• IHD 
• History of CVA or TIA  
• Poor respiratory reserve 
• Significant hepatic/renal disease 
• Patient refusal 
• Hypersensitivity to study drug 
• Not satisfying inclusion criteria 
 
Materials and methods 
• A prospective, randomized study 
• Ethical committee approval 
• Informed consent 
• 40 patients posted for endoscopic sinus surgery were drafted if they 
fulfilled the inclusion criteria 
• Preoperative evaluation included detailed elicitation of significant 
history, clinical evaluation 
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• Preoperative investigation included Hb, PCV, BT, CT, RFT, ECG and 
chest X-ray. 
• Premedication included oral alprazolam 0.5mg 3 hours before surgery 
• Any relevant specialist opinion, investigation and care were obtained 
•  Nasal packing done with 4% lignocaine with oxymetazoline 
• In the operation theatre, IV access was obtained with 18G IV cannula. 
Preloading was done with 10ml/kg of balanced salt solution.  
• Monitoring was done using a L&T monitor which included ECG, NIBP, 
SpO2 and temperature.  
• After recording baseline values and preloading, patients were given the 
drug based on the group they were assigned to. 
• Preoxygenation with 100% oxygen for 3 min. 
• Induction : Fentanyl 2mcg/kg + Propofol 2.5 mg/kg + Rocuronium 0.6 
mg/kg 
• Endotracheal intubation 
• Throat packing 
• In group S, maintenance with 66% N2O, 33% O2, 3% sevoflurane with 
IPPV and rocuronium as relaxant. 
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• In group P, maintenance with 66% N2O, 33% O2, propofol 10mg/kg for 
initial 10 min, 8mg/kg for next 10 min, 6mg/kg till the end of procedure 
with IPPV and rocuronium as relaxant.  
 
Plan 
Plan is to maintain MAP between 60 – 70 mmHg. 
If MAP > 70mmHg:  
 Start a titrated NTG infusion at 0.3µg/kg/min. Increase by 0.3µg/kg/min with an 
interval of 5 min to allow equilibration of serum therapeutic levels. 
 
If MAP < 60mmHg: 
Step 1: IV fluids RL/NS – 200ml 
Step 2: Taper down NTG  
Step 3: IV Ephedrine 6mg bolus 
 
If HR > 150 bpm:  
IV Esmolol bolus 500mcg/kg 
If HR < 50 bpm: 
 IV Atropine 0.6 mg  
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In case of arrhythmias: 
If hemodynamically stable, continue with the study with close and increased 
monitoring. 
If hemodynamically unstable, abandon hypotensive anaesthesia and manage 
accordingly. 
 
End of procedure: 
Reversal with neostigmine 50 µg/kg + glycopyrollate 8 µg/kg and extubation.  
 
Parameters studied 
1. Heart rate  
2. Systolic blood pressure 
3. Diastolic blood pressure 
4. Mean arterial pressure 
5. Requirement of nitroglycerine 
6. Intra operative problems (hypotension, hypertension, arrhythmias, 
tachycardia, bradycardia and ischemia) 
7. Duration of surgery 
8. Operating field 
9. Intra operative blood loss 
10. Post anaesthesia discharge criteria 
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Post anaesthesia discharge scoring system 
 
Score 0 1 2 
Vital signs >40% of 
preoperative 
baseline 
20-40% 
preoperative 
baseline 
Within 20% 
of 
preoperative 
baseline 
 Activity Unable to 
ambulate 
Dyspnoeic, 
requires 
assistance 
Steady gait, 
no dizziness 
or pre-op 
level 
Nausea & 
vomiting 
Continues 
after repeated 
treatment 
Moderate, 
treated with 
IM 
medications 
Minimal, 
treated with 
PO 
medications 
Pain 
(Acceptable 
to the 
patient; 
controlled 
with PO 
meds) 
- No Yes 
Surgical 
bleeding 
Minimal, no 
dressing 
change 
required. 
Moderate, up 
to two 
dressing 
changes. 
Severe, more 
than three 
dressing 
changes. 
 
Score of 9 or more is required to meet the fitness for discharge. 
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Blood loss estimation 
For the assessment of blood loss during the surgery, the blood suctioned from the 
surgical area was collected in a suction bottle to which heparin was added. 
Additionally, the nasal gauze packs soaked with blood were also counted. Each 
gauze strip measured 4 inches long and ½ inch wide holding 2 ml of blood. 
Partially soaked gauze strip holds 1 ml of blood.   
 
Fromme Boezzart scale 
0 = No bleeding. 
1 = Slight bleeding: no suction of blood required 
2 = Slight bleeding: occasional suctioning required. Surgical field not threatened. 
3 = Slight bleeding: frequent suctioning required. Bleeding threatens surgical field 
a few seconds after suction is removed. 
4 = Moderate bleeding: frequent suctioning required. Bleeding threatens surgical 
field directly after suction is removed. 
5 = Severe bleeding: constant suctioning required. Bleeding appears faster than can 
be removed by suction. Surgical field severely threatened.  
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Data management and analysis 
The variables were entered into SPSS, version 11, statistical software for analysis. 
The descriptive statistics of the variables studied are represented as two-way 
tables. The categorical factors are represented by the number and frequency of 
cases. The continuous variables are represented by measures of central frequency 
(like mean, median and mode) and deviation (standard deviation and range). The 
differences in the proportions are tested for statistical significance using non 
parametric chi- square test for variants measured on nominal scale. When testing 
for two groups, student “t” test is used to test for statistical significance in the 
differences of the two means. Line graphs were used to illustrate the hemodynamic 
monitoring at different time points. Box plot graphs were employed to depict the 
distribution of other factors in the two groups.  
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CHAPTER VIII 
OBSERVATION AND RESULTS 
DEMOGRAPHIC DATA 
TABLE I 
Age distribution$ 
$ Not statistically significant 
The mean age between the comparison groups are almost similar. 
The minimum age taken for the study is 20 and maximum is 55. 
 
 
 
 
AGE SEVOFLURANE PROPOFOL p-value 
No. of cases 25 25 
Mean 38.16 37.88 
S.D. 8.18 9.97 
Range 24-55 20-52 
 
 
0.91 
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TABLE II 
Sex distribution$ 
SEVOFLURANE PROPOFOL  
No. % No. % 
 
p-value 
Male 20 80 19 76 
Female 5 20 6 24 
 
1.00 
$ Not statistically significant 
A male preponderance is forthcoming in all the study groups. However, the 
distribution of sex among the groups is not statistically significant. 
 
TABLE III 
Weight distribution$ 
Weight SEVOFLURANE PROPOFOL p-value 
No. of cases 
Mean 
S.D. 
Range 
25 
63.44 
6.49 
50-75 
25 
62.2 
6.78 
50-75 
 
 
0.91 
               $ Not statistically significant 
The mean distribution of cases by weight was observed to be not statistically 
significant between the two groups.  
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TABLE IV 
Intra-operative requirement of Nitroglycerine$ 
SEVOFLURANE PROPOFOL NTG 
used 
No. % No. % 
p-value 
Yes 7 28 6 24 
No 18 72 19 76 
 
0.74 
                      $ Not statistically significant 
Both groups require nitroglycerine intra operatively. There is no statistical 
significance between the two groups in intra-operative requirement of 
nitroglycerine.  
 
TABLE IV 
Intra-operative hemodynamic parameters 
Parameter SEVOFLURANE PROPOFOL p-value 
Heart  rate 
Before induction 78.44±8.40 78.56±9.29 0.96 
After induction 83.88±8.53 81.76±6.89 0.34 
After intubation 89.08±7.73 92.32±7.75 0.15 
Average intra-op 84.56±4.36 73.93±4.97 0.00* 
Immediate post-op 84.48±7.16 79.44±7.97 0.02* 
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Systolic  blood  pressure 
Before induction 124.80±10.04 124.40±8.99 0.88 
After induction 100.92±10.53 107.60±10.10 0.03 
After intubation 125.60±12.13 123.92±15.19 0.67 
Average intra-op 91.09±4.80 92.81±4.17 0.19 
Immediate post-op 124.24±9.93 119.76±9.19 0.10 
Diastolic  blood  pressure 
Before induction 82.28±6.19 82.16±7.77 0.95 
After induction 68.40±8.88 70.08±8.66 0.50 
After intubation 85.52±9.66 83.92±12.09 0.61 
Average intra-op 60.03±2.87 62.00±2.49 0.01* 
Immediate post-op 83.60±6.79 79.04±6.05 0.02 
Mean  arterial  blood  pressure 
Before induction 96.44±7.04 96.20±7.79 0.91 
After induction 79.24±8.63 82.56±8.64 0.18 
After intubation 98.88±10.24 97.36±12.90 0.65 
Average intra-op 70.36±3.13 72.26±2.40 0.02* 
Immediate post-op 97.16±7.30 92.64±6.47 0.03 
     * Statistically significant 
There is a statistically significant difference in the average intra operative heart 
rate. There is a significant reduction in heart rate in the propofol group when 
compared to the sevoflurane group. There is a statistically significant difference in 
the average intra operative systolic blood pressure between the two groups with the 
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sevoflurane group having a lower value. There is a statistically significant 
difference in mean arterial pressure. Between the two groups with the sevoflurane 
group having a lower value.  
 
 
TABLE VI 
Intra operative adverse events$ 
SEVOFLURANE PROPOFOL p-value Intra operative 
problems 
No. % No. %  
Arrhythmia Yes 
No 
0 
20 
0 
100 
0 
20 
0 
100 
 
_ 
Hypotension Yes 
No 
6 
19 
24 
76 
2 
23 
8 
92 
 
0.25 
Hypertension Yes 
No 
0 
20 
0 
100 
0 
20 
0 
100 
 
_ 
Tachycardia Yes 
No 
0 
20 
0 
100 
0 
20 
0 
100 
 
_ 
Bradycardia Yes 
No 
0 
20 
0 
100 
0 
20 
0 
100 
 
_ 
Ischemia Yes 
No 
0 
20 
0 
100 
0 
20 
0 
100 
 
_ 
        $ Not statistically significant 
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Intra operative problems such as tachycardia, bradycardia, arrhythmias, ischemia 
and hypertension are not seen in any of the groups.  Hypotension is the commonest 
recorded adverse event observed in both the groups with six cases in the 
sevoflurane group and four cases in the propofol group. 
 
TABLE VII 
Effect of study drugs on duration of surgery$ 
Duration of 
surgery 
SEVOFLURANE PROPOFOL p-value 
No. of cases 25 25 
Mean 64.8 71.4 
S.D. 16.99 15.24 
Range 30-90 45-100 
 
 
0.16 
            $ Not statistically signicant 
There is no statistically significant difference in the duration of surgery between 
the two groups. 
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TABLE VIII 
Evaluation of surgical field by surgeon 
Fromme 
Boezzart scale 
SEVOFLURANE PROPOFOL p-value 
No. of cases 25 25 
Mean 1.96 1.16 
S.D. 0.2 0.37 
Range 1-2 1-2 
 
 
0.00* 
          * Statistically significant  
Propofol group provided a better Fromme Boezzart score in the evaluation of 
surgical field. This is a statistically significant difference.  
 
TABLE IX 
Intra operative blood loss 
Blood loss SEVOFLURANE PROPOFOL p-value 
No. of cases 25 25 
Mean 156.8 102 
S.D. 91.33 58.83 
Range 25-330 10-210 
 
 
0.02* 
        * Statistically significant 
Propofol group shows statistically significant decrease in the intra operative blood 
loss.  
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TABLE X 
PADSS - 24 hours post op 
SEVOFLURANE PROPOFOL PADSS – 12 
pm 
1st POD 
 
No. 
 
% 
 
No. 
 
% 
9 25 100 25 100 
 
There is no statistically significant difference between the two groups.  
All patients are fit to be discharged 24 hours after surgery. 
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CHAPTER IX 
DISCUSSION 
The primary goal of an anaesthetist in FESS procedure is to provide better surgical 
access, a blood less operating field, conduct of balanced anaesthesia and prompt 
recovery. To provide a blood less operating field, we need to control the three 
sources of bleeding – venous, capillary and arterial. In our study, we have used 
methods to control bleeding from all the three sources. Proper positioning of the 
patients, for example in head and neck surgeries, a 15-20º reversed Trendelenberg 
position promotes venous drainage and reduces bleeding. To control the capillary 
bleeding, the surgeon uses nasal packs with decongestants like oxymetazoline and 
infiltrates the field with 1% lignocaine with 1:1,00,000 adrenaline for 
vasoconstriction. We have used this concentration for standardization. In order to 
control the arterial bleeding, we have used induced hypotension to reduce the mean 
arterial pressure to around 70 mmHg.   
 
This study compares the efficacy of sevoflurane and propofol as maintenance 
anaesthesia in reducing intra operative blood loss and improving the surgical field.  
 57
As per the study, the two groups did not demonstrate any statistical significance in 
demographic distribution.  
 
Both the groups are comparable in their resting heart rate and blood pressure. All 
the patients are normotensive. There is no statistically significant difference 
between the groups.  
 
Since both the groups receive the same mode of induction with similar dosage of 
drugs, intubation responses also did not vary between the two groups.  
                             
Intra operative mean arterial pressure was maintained around 70 mmHg with the 
use of a deep plane of anaesthesia with either sevoflurane or propofol. In patients 
who failed to achieve the targeted mean arterial pressure, the vasodilator 
nitroglycerine was used. In the sevoflurane group, the patient was handed over to 
the surgeon only after a minimum of 15 minutes to allow equilibration of alveolar 
and brain partial pressure to the concentration set in the dial. The flaw in our study 
is the non usage of end tidal agent analyzer due to non availability in our setup. 
Intra operative mean arterial pressure was found to be lower in the sevoflurane 
group. Shigeiki et al11, in their study found that the mean arterial pressure was 
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lower in the propofol group than in the sevoflurane group. The findings in our 
study did not concur with this. The current study also showed that the diastolic 
blood pressure was lower in the sevoflurane group.  
                                 
Nevertheless, the intra operative heart rate was found to be lower in the propofol 
group. This finding concurred with the results of the study by Steinmetz et al12, 
which found that the propofol infusion group was associated with lower heart rate 
than sevoflurane group. This finding also concurs with the results of the study by 
Zeliha et al13, in which preoperative heart rates are lower in the propofol infusion 
for maintenance of anaesthesia group. 
                                 
A comparable number of patients in both the groups required nitroglycerine 
infusion for maintaining the intra operative mean arterial pressure at around 70 
mmHg. There was no statistically significant relevance in these findings. 
                                 
Intra operative problems like hypertension, arrhythmia, tachycardia and ischemia 
were not encountered in either of the groups. 
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Hypotension was the most common intra operative problem encountered with 6 
(24%) patients in the sevoflurane group and 2 (8%) in the propofol group. Our 
findings did not concur with the results of the study by Jellish et al14, which states 
that both propofol and sevoflurane groups are hemodynamically stable throughout 
the study period. The results of the study by Watson et al15, that cardiovascular 
stability was good and comparable  in both the groups seems to support our study. 
                                
There is no statistically significant difference in the duration of surgery between 
the two groups.  
                                
In the evaluation of the surgical field by surgeon using Fromme Boezzart scale, 
propofol group provided a better score over sevoflurane group. This finding 
concurs with the results of the study by Eberhart et al7.  
                               
There is a marked difference in the intra operative blood loss between the two 
groups with propofol group providing the least blood loss. The lower intra 
operative heart rate leading to lower cardiac output in the propofol group may be 
accounted for the lower blood loss and better surgical field.  
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All the patients in both the groups met the discharge criteria 24 hours after the 
surgery. Discharge criteria was assessed only after 24 hours because in this 
institute, patients undergoing FESS surgery have their nasal packs changed to 
evaluate for bleeding. Hence they are not discharged prior to 24 hours. 
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CHAPTER X 
SUMMARY 
The prospective randomized study aimed to compare the effects of sevoflurane and 
propofol as maintenance anaesthetics on peri-operative characteristics of patients 
undergoing FESS procedure under general anaesthesia and induced hypotensive 
anaesthetic technique. 
 
Important conclusions from this study include 
1. Both drugs provide good to excellent conditions during maintenance of 
anaesthesia.  
2. Sevoflurane lowered intra operative blood pressures better than propofol 
anaesthesia. 
3. Propofol produces lower intra operative heart rate than sevoflurane anaesthesia. 
4. Sevoflurane anaesthesia causes more incidence of intra operative hypotension 
than propofol based anaesthesia. 
5. Propofol anaesthesia provided better visualization of the surgical field assessed 
by the surgeon using Fromme Boezzart scale. 
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6. Propofol based anaesthesia reduces intra operative blood loss compared to 
sevoflurane anaesthesia. 
7. Propofol and sevoflurane based anaesthesia causes easily reversible induced 
hypotension. It did not extend into the post operative period nor was there any 
rebound hypertension.  
8. A few patients in both sevoflurane and propofol groups require vasodilator 
nitroglycerine to achieve the target mean arterial pressure.  
9. Lack of usage of end tidal agent analyser was a limiting factor in the study. 
10. Balanced anaesthesia technique with meticulous attention to patient’s needs is 
the single most important factor in production of controlled hypotension during 
surgery with propofol anaesthesia reducing the intra operative blood loss. 
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CHAPTER XI 
CONCLUSION 
Sevoflurane and propofol based anaesthesia produce comparable and excellent 
intra-operative conditions during anaesthesia for FESS. 
                         
 Sevoflurane group produced superior blood pressure control, while propofol had 
lower and more stable heart rates. 
 
 Propofol based anaesthesia had lesser intra operative blood loss and provided 
better visualization.  
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PROFORMA 
DEPARTMENT OF ANAESTHESIOLOGY, 
MADRAS MEDICAL COLLEGE, CHENNAI. 
 
 
A COMPARITIVE EVALUATION OF PROPOFOL AND 
SEVOFLURANE BASED ANAESTHETIC TECHNIQUE ON PERI 
OPERATIVE PARAMETERS OF PATIENTS UNDERGOING FESS 
UNDER HYPOTENSIVE ANAESTHESIA 
 
Name:       
Age/Sex: 
Diagnosis: 
Surgery:                                
Pre op assessment:     
Airway:  
Comorbid illness: 
Drug therapy: 
 
ASA Height Weight 
   
 
Name       
Age/Sex 
Diagnosis 
Surgery                                
Pre op assessment     
Airway  
Comorbid illness 
Drug therapy 
 
INVESTIGATIONS 
 
 
PREMED 
 Alprax 
5 mg 
Time Ranitidine 
150 mg 
Time 
    
    
 
Nasal Pack Drug Volume 
 
  
 
 
 
 
 
 
 
 
 
 
GA with CV 
Induction 
Fent 
2µg/kg 
Propofol 
2.5mg/kg 
 
Rocuronium
0.6mg/kg 
 
ETT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
      
 
       MONITORS 
 
ECG NIBP SPO2 Temp. 
    
 
 
 
        
 
 
 
 
 
 
                                        
ASA Height Weight 
   
Hb PCV BT CT Sugar Creatinine Platelets 
       
 
IV Access 18 G 
 
 
 
 
 
 
Infiltration 1% Lignocaine with 1:100000 
Adrenaline 
           Volume 
 
Maintenance 
 
INTRA OP EVENTS 
 
 
 
Episodes 
 
Treatment 
 
Hypotension  MAP < 60   
Hypertension MAP > 80   
Bradycardia  HR < 50   
 Tachycardia HR > 150   
Desaturation, Ischemia   
 
INTRA OP HEMODYNAMIC PARAMETERS 
 
                                 
HR                                 
SBP                                 
DBP                                 
MAP                                 
SPO2                                 
 
Duration of surgery  
 
Total blood loss Suction Pads/Gauze Surgical field 
 
 
   
 
Reversal Extubation 
Neostigmine Glycopyrrolate 
  
 
 
Post Op:       
 
HR:        Consciousness: 
        CVS: 
BP:        RS: 
PADSS : 
                               
Sevo                               
Fent .5µg/kg                              
Roc .2mg/kg                              
NTG                               
